Prosecution Insights
Prosecution Insights
14 pending office actions • 10 art units • 13 examiners • 0 of 14 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 6 (43%) |
| §112 only | 4 (29%) |
| Double-patenting only | 1 (7%) |
| Double-patenting + other | 2 (14%) |
| No statute on record | 1 (7%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WEHBE, ANNE MARIE SABRINA | 2 | 57.4% | +42.6% |
| ZOU, NIANXIANG | 1 | 64.0% | +24.8% |
| DAUNER, JOSEPH G | 1 | 56.8% | +35.4% |
| DRISCOLL, MAUREEN VARINA | 1 | 64.2% | +43.7% |
| ARON, KIMBERLY A | 1 | 54.7% | +34.9% |
| DUNN, LINDSAY MICHELLE | 1 | 100.0% | +0.0% |
| ZHU, JIANJIAN | 1 | 60.0% | +83.2% |
| CHANDRAKUMAR, NIZAL S | 1 | 72.6% | +18.3% |
| CANELLA, KAREN A | 1 | 62.5% | +32.5% |
| SUNSHINE, HANNAH LOUISE | 1 | 70.0% | +11.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18365950 | CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR GPRC5D AND BCMA | DUNN, LINDSAY MICHELLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17850875 | METHODS FOR ISOLATING, CULTURING, AND GENETICALLY ENGINEERING IMMUNE CELL POPULATIONS FOR ADOPTIVE THERAPY | WEHBE, ANNE MARIE SABRINA | 31d overdue |
| 18019460 | ANTI-IDIOTYPIC ANTIBODIES TO ROR1-TARGETED BINDING DOMAINS AND RELATED COMPOSITIONS AND METHODS | SUNSHINE, HANNAH LOUISE | 8d overdue |
| 18488850 | EPIGENETIC ANALYSIS OF CELL THERAPY AND RELATED METHODS | DAUNER, JOSEPH G | 47d |
| 18188380 | METHODS AND COMPOSITIONS FOR DOSING IN ADOPTIVE CELL THERAPY | CANELLA, KAREN A | 63d |
| 18035280 | CAR T CELL THERAPY IN PATIENTS WHO HAVE HAD PRIOR ANTI-CANCER ALKYLATOR THERAPY | CHANDRAKUMAR, NIZAL S | 70d |
| 19312145 | METHODS FOR ISOLATING, CULTURING, AND GENETICALLY ENGINEERING IMMUNE CELL POPULATIONS FOR ADOPTIVE THERAPY | WEHBE, ANNE MARIE SABRINA | — |
| 18283435 | METHOD TO ASSESS POTENCY OF VIRAL VECTOR PARTICLES | ZOU, NIANXIANG | — |
| 18284725 | METHODS FOR DOSING AND TREATMENT WITH A COMBINATION OF A CHECKPOINT INHIBITOR THERAPY AND A CAR T CELL THERAPY | DRISCOLL, MAUREEN VARINA | — |
| Art Unit | Apps |
|---|---|
| 1634 | 2 |
| 1633 | 2 |
| 1643 | 2 |
| 1682 | 1 |
| 1645 | 1 |
| 1644 | 1 |
| 1625 | 1 |
| 1647 | 1 |
| 1631 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19312145 | METHODS FOR ISOLATING, CULTURING, AND GENETICALLY ENGINEERING IMMUNE CELL POPULATIONS FOR ADOPTIVE THERAPY | WEHBE, ANNE MARIE SABRINA | 1634 | §103 | Final Rejection | — | Pending | Aug 27, 2025 |
| 18283435 | METHOD TO ASSESS POTENCY OF VIRAL VECTOR PARTICLES | ZOU, NIANXIANG | — | §103 | Non-Final OA | — | Pending | May 13, 2024 |
| 18488850 | EPIGENETIC ANALYSIS OF CELL THERAPY AND RELATED METHODS | DAUNER, JOSEPH G | 1682 | §103 | Final Rejection | 47d | Pending | Oct 17, 2023 |
| 18284725 | METHODS FOR DOSING AND TREATMENT WITH A COMBINATION OF A CHECKPOINT INHIBITOR THERAPY AND A CAR T CELL THERAPY | DRISCOLL, MAUREEN VARINA | 1645 | DP | Non-Final OA | — | Pending | Sep 28, 2023 |
| 18371302 | METHODS FOR TRANSDUCTION AND CELL PROCESSING | ARON, KIMBERLY A | 1633 | Other | Non-Final OA | — | Pending | Sep 21, 2023 |
| 18365950 | CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR GPRC5D AND BCMA | DUNN, LINDSAY MICHELLE | 1644 | §112 | Non-Final OA | — | Pending | Aug 04, 2023 |
| 18035277 | CELLS EXPRESSING A CHIMERIC RECEPTOR FROM A MODIFIED INVARIANT CD3 IMMUNOGLOBULIN SUPERFAMILY CHAIN LOCUS AND RELATED POLYNUCLEOTIDES AND METHODS | ZHU, JIANJIAN | 1633 | §103 | Non-Final OA | — | Pending | May 03, 2023 |
| 18035280 | CAR T CELL THERAPY IN PATIENTS WHO HAVE HAD PRIOR ANTI-CANCER ALKYLATOR THERAPY | CHANDRAKUMAR, NIZAL S | 1625 | DPOther | Non-Final OA | 70d | Pending | May 03, 2023 |
| 18188380 | METHODS AND COMPOSITIONS FOR DOSING IN ADOPTIVE CELL THERAPY | CANELLA, KAREN A | 1643 | DPOther | Non-Final OA | 63d | Pending | Mar 22, 2023 |
| 18019460 | ANTI-IDIOTYPIC ANTIBODIES TO ROR1-TARGETED BINDING DOMAINS AND RELATED COMPOSITIONS AND METHODS | SUNSHINE, HANNAH LOUISE | 1647 | §112 | Non-Final OA | 8d overdue | Pending | Feb 02, 2023 |
| 17799239 | BCMA-DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL COMPOSITIONS AND METHODS AND USES THEREOF | GRABER, JAMES J | 1631 | §112 | Final Rejection | 18d overdue | Pending | Aug 11, 2022 |
| 17799254 | CD19-DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL COMPOSITIONS AND METHODS AND USES THEREOF | EDGINGTONGIORDANO, FRANCESCA | 1643 | §103 | Non-Final OA | — | Pending | Aug 11, 2022 |
| 17850875 | METHODS FOR ISOLATING, CULTURING, AND GENETICALLY ENGINEERING IMMUNE CELL POPULATIONS FOR ADOPTIVE THERAPY | WEHBE, ANNE MARIE SABRINA | 1634 | §103 | Final Rejection | 31d overdue | Pending | Jun 27, 2022 |
| 17294355 | METHODS OF DOSING ENGINEERED T CELLS FOR THE TREATMENT OF B CELL MALIGNANCIES | TAYLOR, LIA ELAN | 1641 | §112 | Final Rejection | — | Pending | May 14, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial